.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,512,297

« Back to Dashboard

Details for Patent: 5,512,297

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs
Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY)
Assignee: Edward Mendell Co., Inc. (Patterson, NY)
Filing Date:May 22, 1995
Application Number:08/447,235
Claims:1. A method of preparing a oral extended release formulation of a medicament having poor solubility in water, comprising:

preparing a sustained release excipient comprising from about 10 to about 99 percent by weight of a gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, the ratio of said heteropolysaccharide gum to said homopolysaccharide gum being from about 1:3 to about 3:1, from about 1 to about 20 percent by weight of a cationic crosslinking agent capable of crosslinking with said gelling agent to increase the gel strength when exposed to an environmental fluid, and from about 0 to about 89 percent by weight of an inert pharmaceutical diluent; and

adding an effective amount of a medicament having a solubility of less than about 10 g/l to render a desired therapeutic effect, such that a final product is obtained having a ratio of said medicament to said gelling agent from about 1:3 to about 1:8, such that a gel matrix is created when said formulation is exposed to environmental fluid and said formulation provides therapeutically effective blood levels of said medicament for at least 12 hours.

2. The method of claim 1, further comprising tableting said mixture of said sustained release excipient and said medicament.

3. The method of claim 2, further comprising coating said tablets with a hydrophobic coating to a weight gain from about 1% to about 20%.

4. The method of claim 1, further comprising granulating said sustained release excipient with a hydrophobic material.

5. The method of claim 1, wherein said medicament is nifedipine.

6. The method of claim 1, wherein said cationic cross-linking agent is calcium sulfate.

7. The method of claim 1, wherein said hydrophobic coating comprises ethylcellulose.

8. The method of claim 1, further comprising wetting said medicament with an effective amount of a pharmaceutically acceptable wetting agent prior to blending said medicament with said sustained release excipient.

9. The method of claim 8, wherein said wetting agent comprises polyethylene glycol.

10. The method of claim 8, further comprising coating said mixture of said sustained release excipient, said medicament and said wetting agent with a hydrophobic material.

11. The method of claim 1, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg or 90 mg.

12. The method of claim 1, wherein said sustained release excipient comprises from about 10 to about 75 percent gelling agent, from about 2 to about 15 percent cationic crosslinking agent, and from about 30 to about 75 percent inert diluent.

13. The method of claim 1, wherein said sustained release excipient comprises from about 30 to about 75 percent gelling agent, from about 5 to about 10 percent cationic crosslinking agent, and from about 15 to about 65 percent inert diluent.

14. The method of claim 1, wherein said formulation provides therapeutically effective blood levels of said medicament for at least 24 hours.

15. The method of claim 1, further comprising compressing the mixture of said sustained release excipient and said tablet into tablets.

16. A method for preparing a sustained release oral solid dosage form for a drug having a solubility of less than about 10 g/l, comprising

preparing a sustained release excipient comprising a gelling agent and a cationic crosslinking agent in an amount effective to crosslink said gelling agent when said gelling agent is exposed to fluid in an environment of use;

preparing a granulate of an effective amount of a medicament having a solubility of less than about 10 g/l with a pharmaceutically acceptable wetting agent, mixing said wetted medicament with said sustained release excipient;

coating said granulate with a hydrophobic material to a weight gain from about 1% to about 20%; and

preparing an oral solid dosage form suitable for human consumption by compressing an appropriate amount of said coated granulate into a tablet, or by incorporating an appropriate amount of said coated granulate into a gelatin capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc